• The Yield Growth Corp. (BOSS) subsidiary, Flourish Mushroom Labs, has acquired an 18 per cent stake in Translational Life Sciences
  • A biotech start-up, Translational Life Sciences focuses on using psilocybin and cannabis to treat an array of conditions and illnesses
  • As consideration for the deal, Flourish Mushroom Labs issued 15,000,000 shares and 15,000,000 warrants to purchase an additional share at C$0.50
  • The 18% stake in Translational Life Sciences is estimated to be worth $750,000
  • Shares in Yield Growth are currently trading at C$0.28, with a market cap of C$28.45 million

Flourish Mushroom Labs, a subsidiary of Yield Growth (BOSS), has acquired an 18% stake in biotechnology start-up Translational Life Sciences.

Translational Life Sciences is focused on the development of proprietary medicinal formulations to treat an array of conditions and illnesses using psilocybin and cannabis.

With an aim to provide solutions to currently unmet needs, the company also offers services to design and manage clinical trials of restricted substances for third parties.

“As a founder in TLS, we will now work with TLS to increase the value of our investment by helping it build out its management team, raise additional capital and complete its plans to develop intellectual property in plant-based medicine,” said Yield Growth and Flourish Mushroom Labs CEO, Penny White.

“We believe our alliance with TLS will help establish us as a leader in the emerging industry of psychedelic medicine.”

Translational Life Sciences is spearheaded by an expert team of physicians and scientists with histories in neurology, pharmacology, pain management, addiction and biochemistry, as well as significant experience in the clinical application of cannabinoid compounds.

As consideration for the deal, Flourish Mushroom Labs issued 15,000,000 units in the company. Each unit of Flourish comprises of one share and one warrant to acquire an additional share at C$0.50.

Flourish Mushroom Labs’ 18 per cent stake is estimated to be worth roughly C$750,000.

With 130 deaths attributed to opioid overdoses each day in the United States, the potential for psychedelic compounds to treat a host of health complications, including addiction, is becoming a subject of increasing focus.

Shares in Yield Growth are currently trading at C$0.28, with a market cap of C$28.45 million.

More From The Market Online
Cannabis Report in text over top a photo of cannabis leaves

The Market Online’s Weekly Cannabis Report – July 12, 2024

A Vancouver cannabis stock has been authorized to be able to legally domestically produce and sell CBD products in Mexico.
Cannabis leaves with Stock Talk and Cannabis Report labels

The Market Online’s Weekly Cannabis Report – July 5, 2024

The second-largest cannabis retailer in North America by store count will open two Canna Cabana stores later this month.
CBD oil on marijuana leaves

Xebra Brands completes manufacturing run for Elements brand

Xebra Brands (CSE:XBRA) completes the first manufacturing run of its Elements line that includes capsules, tinctures, topicals and oils.